Linden Capital Partners has closed its fourth private equity fund, Linden Capital Partners IV LP, at the hard cap of $1.5 billion. Fund IV was oversubscribed and exceeded its target of $1.25 billion.
Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries with a specific interest in medical products, specialty distribution, pharmaceutical, and services segments of healthcare. Linden’s strategy is based on three elements: healthcare and life science industry specialization; integrated financial and operating expertise; and strategic relationships with large corporations. The firm is based in Chicago (www.lindenllc.com).
“We truly appreciate the support from our investors, which include endowments, global financial institutions, and pension funds,” said Tony Davis, Linden’s President and Managing Partner. “Linden will continue to execute its consistent strategy in Fund IV. This strategy consists of implementing its proprietary value creation programs, emphasizing human capital, and leveraging the integrated expertise of its operating partners and investment professionals to build market-leading healthcare companies.”
Linden closed its first fund of $200 million in 2005, its second fund of $375 million in 2010, and its third fund of $750 million in 2015. During the investment phase of its third fund, Linden expanded its resources with the addition of four new investment professionals, five new operating partners, and an additional member to the firm’s finance team.
Park Hill Group (www.parkhillgroup.com) was the placement agent for this fundraise.
© 2018 Private Equity Professional | May 9, 2018